urinary tract infection
MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive
Illnesses caused by Streptococcus pneumoniae are currently considered a major public health problem by WHO
MHRA approves Bavarian Nordic’s chikungunya vaccine Vimkunya
Approximately 620,000 cases of the mosquito-borne viral disease were reported worldwide in 2024
MHRA urges companies to prepare for Windsor Framework for medicines
The new UK-wide arrangements for medicines will come into effect on 1 January 2025
Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults
Approximately 25,000 people in the UK are affected by the rare liver disease
Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine approved by MHRA
The UK regulator has approved four versions of the updated vaccine for adults and children from infancy
Novo Nordisk’s semaglutide approved by MHRA to prevent cardiovascular event risk
Approximately 7.6 million people are living with heart and circulatory diseases in the UK
MHRA approves first generic raltegravir medicines to treat HIV in adults and children
More than 91,000 people in England were diagnosed with HIV and accessing care in 2022
UCB’s Bimzelx granted MHRA approval to treat hidradenitis suppurativa in adults
The authorisation applies to patients who have had an inadequate response to conventional systemic HS therapy
Takeda’s Takhzyro granted MHRA approval for younger hereditary angioedema patients
The rare genetic disorder is estimated to affect one in every 50,000 people
MHRA approves TMC Pharma’s Nulibry to treat rare genetic disease MoCD type A
Molybdenum cofactor deficiency is estimated to affect one in 100,000 to 200,000 newborns worldwide
MHRA approves Advanz Pharma’s combined antibiotic to treat complicated infections
In England, approximately 130,000 patients are affected by bloodstream infections every year
Takeda’s HyQvia receives MHRA approval for rare neurological disorder CIDP
The therapy offers patients with CIDP a typical dosing interval of four weeks